• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Coherus BioSciences Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket

    1/22/24 8:21:24 AM ET
    $ACRS
    $ADM
    $AGFY
    $ASTL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Packaged Foods
    Consumer Staples
    Get the next $ACRS alert in real time by email

    Shares of Coherus BioSciences, Inc. (NASDAQ:CHRS) shares rose sharply in today’s pre-market trading after the company announced an agreement to divest ophthalmology franchise to Sandoz in $170 million upfront all cash deal.

    Coherus BioSciences shares jumped 22.1% to $2.98 in pre-market trading

    Here are some other stocks moving in pre-market trading.

    Gainers

    • Northann Corp. (NYSE:NCL) shares jumped 19.9% to $1.63 in pre-market trading after jumping over 25% on Friday.
    • HNR Acquisition Corp (NYSE:HNRA) gained 15.4% to $2.48 in pre-market trading.
    • Porch Group, Inc. (NASDAQ:PRCH) gained 15.4% to $2.55 in pre-market trading.
    • TC Biopharm (Holdings) Plc (NASDAQ:TCBP) surged 15% to $2.69 in pre-market trading after gaining over 10% on Friday. TC BioPharm recently regained compliance with Nasdaq minimum bid price requirement.
    • Remark Holdings, Inc. (NASDAQ:MARK) shares climbed 12.7% to $0.4340 in pre-market trading after falling more than 10% on Friday.
    • Unicycive Therapeutics, Inc. (NASDAQ:UNCY) shares gained 11.8% to $0.9690 in pre-market trading.
    • Aclaris Therapeutics, Inc. (NASDAQ:ACRS) gained 10.5% to $1.26 in pre-market trading. Aclaris Therapeutics recently announced leadership changes as the company undertakes a strategic review of its business.
    • Genius Group Limited (NYSE:GNS) shares gained 9.4% to $0.3195 in pre-market trading after gaining around 9% on Friday. Genius Group recently announced closing of $8.25 million public offering.
    • Greenbrook TMS Inc. (NASDAQ:GBNH) shares rose 8.9% to $0.2940 in pre-market trading. Greenbrook TMS raised $1.5 million in debt financing.

    Losers

    • B. Riley Financial, Inc. (NASDAQ:RILY) shares dipped 17.5% to $16.63 in pre-market trading. B. Riley Financial issued a statement in response to a Bloomberg news article published on Jan. 21, 2024.
    • Agrify Corporation (NASDAQ:AGFY) shares fell 14.2% to $0.91 in pre-market trading after declining around 23% on Friday. Agrify recently entered into a multi-million dollar sales agreement with Ocean Deep/Golden Lake Business Park.
    • HUB Cyber Security Ltd. (NASDAQ:HUBC) shares fell 11.8% to $1.50 in pre-market trading after declining 11% on Friday.
    • Airspan Networks Holdings Inc (NASDAQ:MIMO) declined 11.3% to $0.1872 in pre-market trading after surging 24% on Friday. Airspan recently announced a partnership with GCT Semiconductor to develop an RF module.
    • Treasure Global Inc. (NASDAQ:TGL) shares fell 10.9% to $0.10 in pre-market trading after gaining 9% on Friday.
    • Archer-Daniels-Midland Company (NYSE:ADM) fell 9.6% to $61.67 in pre-market trading after the company named Ismael Roig as Interim Chief Financial Officer. ADM said it now expects an adjusted earnings per share of $6.90 for the fiscal year ended Dec. 2023.
    • WiSA Technologies, Inc. (NASDAQ:WISA) shares dipped 8.7% to $0.0973 in pre-market trading after declining over 3% on Friday.
    • Algoma Steel Group Inc. (NASDAQ:ASTL) shares declined 8.3% to $8.32 in pre-market trading. Algoma Steel Group announced that in the early hours of Jan. 20, 2024 there was a collapse of a structure supporting utilities piping at our coke-making plant.
    • Celularity Inc. (NASDAQ:CELU) shares declined 6.4% to $0.2750 in pre-market trading. For full year 2023 the company recently said it expects net sales percentage growth in the range of 22.7% to 26.6% year over year.
    • C3is Inc. (NASDAQ:CISS) fell 5.6% to $0.1277 after falling 6% on Wednesday. C3is shares dipped 64% on Friday after the company announced pricing of its $7 million upsized underwritten public offering.

     

    Now Read This: United Airlines, Brown & Brown And 3 Stocks To Watch Heading Into Monday

    Get the next $ACRS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACRS
    $ADM
    $AGFY
    $ASTL

    CompanyDatePrice TargetRatingAnalyst
    Porch Group Inc.
    $PRCH
    2/11/2026$10.50Mkt Perform → Outperform
    Keefe Bruyette
    Coherus Oncology Inc.
    $CHRS
    1/23/2026$10.00Outperform
    Oppenheimer
    Archer-Daniels-Midland Company
    $ADM
    12/16/2025$50.00Equal-Weight → Underweight
    Morgan Stanley
    Archer-Daniels-Midland Company
    $ADM
    11/5/2025$59.00Neutral → Underweight
    Analyst
    Coherus Oncology Inc.
    $CHRS
    9/4/2025Hold → Buy
    Maxim Group
    Porch Group Inc.
    $PRCH
    9/2/2025$21.00Buy
    Goldman
    Archer-Daniels-Midland Company
    $ADM
    8/20/2025$61.00Neutral
    Analyst
    Archer-Daniels-Midland Company
    $ADM
    8/6/2025$61.00Underweight → Equal Weight
    Barclays
    More analyst ratings

    $ACRS
    $ADM
    $AGFY
    $ASTL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Mcmurray Michael C.

    3 - Archer-Daniels-Midland Co (0000007084) (Issuer)

    3/18/26 4:49:05 PM ET
    $ADM
    Packaged Foods
    Consumer Staples

    SEC Form 3 filed by new insider Kostogiannis Ioannis

    3 - C3is Inc. (0001951067) (Issuer)

    3/18/26 4:28:54 PM ET
    $CISS
    Marine Transportation
    Consumer Discretionary

    SEC Form 3 filed by new insider Xiradakis Georgios

    3 - C3is Inc. (0001951067) (Issuer)

    3/18/26 4:22:52 PM ET
    $CISS
    Marine Transportation
    Consumer Discretionary

    $ACRS
    $ADM
    $AGFY
    $ASTL
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for CIMERLI issued to COHERUS BIOSCIENCES INC

    Submission status for COHERUS BIOSCIENCES INC's drug CIMERLI (SUPPL-5) with active ingredient RANIBIZUMAB-EQRN has changed to 'Approval' on 05/21/2024. Application Category: BLA, Application Number: 761165, Application Classification:

    5/22/24 9:41:01 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for LOQTORZI issued to COHERUS BIOSCIENCES INC

    Submission status for COHERUS BIOSCIENCES INC's drug LOQTORZI (SUPPL-1) with active ingredient TORIPALIMAB-TPZI has changed to 'Approval' on 04/22/2024. Application Category: BLA, Application Number: 761240, Application Classification:

    4/23/24 4:41:07 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for UDENYCA issued to COHERUS BIOSCIENCES INC

    Submission status for COHERUS BIOSCIENCES INC's drug UDENYCA (SUPPL-15) with active ingredient PEGFILGRASTIM-CBQV has changed to 'Approval' on 12/22/2023. Application Category: BLA, Application Number: 761039, Application Classification:

    12/27/23 4:38:39 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACRS
    $ADM
    $AGFY
    $ASTL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ethisphere Names ADM as One of the 2026 World's Most Ethical Companies for 7th Year in a Row

    20th annual recognition honors organizations committed to business integrity through robust ethics, compliance, and governance programs ADM (NYSE:ADM), a global leader in innovative solutions from nature, has been recognized as one of the 2026 World's Most Ethical Companies® by Ethisphere, a global leader in defining and advancing the standards of ethical business practices. ADM has been recognized every year since 2020 and is one of only 9 honorees in the food, beverage, and agriculture category, reflecting the company's consistent focus on fostering a strong, ethical culture across its global operations. In 2026, 138 honorees were recognized, spanning 17 countries and 40 industries. T

    3/18/26 9:10:00 AM ET
    $ADM
    Packaged Foods
    Consumer Staples

    Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

    - Top Line Results Expected in the Fourth Quarter of 2026 - WAYNE, Pa., March 18, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it has completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of bosakitug (ATI-045) in patients with moderate-to-severe atopic dermatitis (AD). Top line results are expected in the fourth quarter of 2026. "The strong interest in participating in this Phase 2 trial reflects the urgent need for innovative solutions in atopic dermatitis and the excitement surrou

    3/18/26 6:55:00 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BRC Group Holdings, Inc. Announces Fourth Quarter and Full Year 2025 Earnings Call

    LOS ANGELES, March 17, 2026 /PRNewswire/ -- BRC Group Holdings, Inc. (NASDAQ:RILY) ("BRCGH" or the "Company"), today announced that it will host its fourth quarter and full year 2025 earnings call on March 31, 2026 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss its financial results. Fourth Quarter and Full Year 2025 Earnings CallManagement will provide a detailed review of the Company's financial performance and operational highlights, followed by a question-and-answer session with analysts and investors.Date:Tuesday, March 31, 2026Time:4:30 p.m. ET (1:30 p.m. PT)Register for the call at https://evercall.co/oacc/83354 or on the Company's website at ir.brcgh.com under Events a

    3/17/26 4:01:00 PM ET
    $RILY
    Investment Managers
    Finance

    $ACRS
    $ADM
    $AGFY
    $ASTL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Porch Group upgraded by Keefe Bruyette with a new price target

    Keefe Bruyette upgraded Porch Group from Mkt Perform to Outperform and set a new price target of $10.50

    2/11/26 7:42:24 AM ET
    $PRCH
    Computer Software: Prepackaged Software
    Technology

    Oppenheimer initiated coverage on Coherus BioSciences with a new price target

    Oppenheimer initiated coverage of Coherus BioSciences with a rating of Outperform and set a new price target of $10.00

    1/23/26 8:18:28 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ADM downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded ADM from Equal-Weight to Underweight and set a new price target of $50.00

    12/16/25 8:40:54 AM ET
    $ADM
    Packaged Foods
    Consumer Staples

    $ACRS
    $ADM
    $AGFY
    $ASTL
    SEC Filings

    View All

    SEC Form NT 10-K filed by BRC Group Holdings Inc.

    NT 10-K - BRC Group Holdings, Inc. (0001464790) (Filer)

    3/17/26 4:15:12 PM ET
    $RILY
    Investment Managers
    Finance

    SEC Form SCHEDULE 13G filed by BRC Group Holdings Inc.

    SCHEDULE 13G - BRC Group Holdings, Inc. (0001464790) (Subject)

    3/16/26 8:00:18 PM ET
    $RILY
    Investment Managers
    Finance

    BRC Group Holdings Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - BRC Group Holdings, Inc. (0001464790) (Filer)

    3/12/26 4:52:52 PM ET
    $RILY
    Investment Managers
    Finance

    $ACRS
    $ADM
    $AGFY
    $ASTL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mcatee David R Ii bought $486,720 worth of shares (7,500 units at $64.90) (SEC Form 4)

    4 - Archer-Daniels-Midland Co (0000007084) (Issuer)

    2/9/26 5:27:53 PM ET
    $ADM
    Packaged Foods
    Consumer Staples

    Interim CEO Kovler Benjamin bought $36,700 worth of shares (1,000 units at $36.70), increasing direct ownership by 6% to 17,000 units (SEC Form 4)

    4 - RYTHM, Inc. (0001800637) (Issuer)

    9/3/25 4:35:48 PM ET
    $AGFY
    Farming/Seeds/Milling
    Consumer Staples

    Interim CEO Kovler Benjamin bought $46,700 worth of shares (1,000 units at $46.70), increasing direct ownership by 7% to 16,000 units (SEC Form 4)

    4 - RYTHM, Inc. (0001800637) (Issuer)

    9/2/25 4:36:32 PM ET
    $AGFY
    Farming/Seeds/Milling
    Consumer Staples

    $ACRS
    $ADM
    $AGFY
    $ASTL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Agrify Corporation

    SC 13D/A - Agrify Corp (0001800637) (Subject)

    11/29/24 4:30:03 PM ET
    $AGFY
    Farming/Seeds/Milling
    Consumer Staples

    Amendment: SEC Form SC 13D/A filed by Agrify Corporation

    SC 13D/A - Agrify Corp (0001800637) (Subject)

    11/29/24 4:30:03 PM ET
    $AGFY
    Farming/Seeds/Milling
    Consumer Staples

    SEC Form SC 13G filed by Aclaris Therapeutics Inc.

    SC 13G - Aclaris Therapeutics, Inc. (0001557746) (Subject)

    11/25/24 11:02:19 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRS
    $ADM
    $AGFY
    $ASTL
    Financials

    Live finance-specific insights

    View All

    Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026

    REDWOOD CITY, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today announced that its full year and fourth quarter 2025 financial results will be released after market close on Monday, March 9, 2026. Starting at 4:30 p.m. Eastern Time on March 9, 2026, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call. Conference Call Information When: Monday, March 9, 2026, starting at 4:30 p.m. Eastern Standard Time To access the conference call, please pre-register

    3/2/26 9:30:00 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Algoma Steel Group Inc. to Announce 2025 Fourth Quarter and Full Year Results March 11, 2026

    SAULT STE. MARIE, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Algoma Steel Group Inc. (NASDAQ:ASTL, TSX:ASTL) ("Algoma" or "the Company"), a leading Canadian producer of steel plate and hot rolled sheet products, announced today that the Company will release its 2025 fourth quarter and full year financial results after the market closes on Wednesday, March 11, 2026. A webcast and conference call will be held on Thursday, March 12, 2026 at 11:00 a.m. Eastern Time to review the Company's results, discuss recent events, and conduct a question-and-answer session. The live webcast and archived replay of the conference call can be accessed on the Investors section of the Company's website at www.ir.algom

    2/26/26 5:30:00 PM ET
    $ASTL
    Steel/Iron Ore
    Industrials

    Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

    - Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Support Rapid Clinical Advancement; Complete Top Line Results Expected in the Second Quarter of 2026 - - Phase 1b Proof-of-Concept Trials of ATI-052 in Atopic Dermatitis (AD) and Asthma Underway; Top Line Results from Both Trials Anticipated in the Second Half of 2026 - - Investigational New Drug (IND) Application for Lead ITK Inhibitor Candidate ATI-9494 Expected in the SecondHalf of 2026 - - ATI-2138, Aclaris' Investigational Inhibitor of ITK and JAK3, Demonstrated Potential Best-in-Class Hair Regrowth in Murine Alopecia Model -  WAYNE, Pa., Feb. 26,

    2/26/26 6:58:00 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRS
    $ADM
    $AGFY
    $ASTL
    Leadership Updates

    Live Leadership Updates

    View All

    Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

    - Top Line Results Expected in the Fourth Quarter of 2026 - WAYNE, Pa., March 18, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it has completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of bosakitug (ATI-045) in patients with moderate-to-severe atopic dermatitis (AD). Top line results are expected in the fourth quarter of 2026. "The strong interest in participating in this Phase 2 trial reflects the urgent need for innovative solutions in atopic dermatitis and the excitement surrou

    3/18/26 6:55:00 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BRC Group Holdings, Inc. Announces Retirement of Approximately $37.9 Million in Outstanding Debt Through Bond-for-Equity Exchanges and Repurchases

    Redemption of Approximately $96 Million of  5.50% Senior Notes due 2026 (RILYK) on March 30, 2026Fourth Quarter and Full Year 2025 Financial Results to be Released by March 31, 2026 LOS ANGELES, March 12, 2026 /PRNewswire/ -- BRC Group Holdings, Inc. (NASDAQ:RILY) ("BRCGH" or the "Company"), today announced a series of transactions with a long-time institutional investor pursuant to Section 3(a)(9) of the Securities Act of 1933, which will, upon closing of the final transaction, result in the cancellation of 1,343,551 units of its publicly-traded senior notes across multiple outstanding series in exchange for the issuance of an aggregate of 4,201,300 shares of the Company's common stock at a

    3/12/26 4:45:00 PM ET
    $RILY
    Investment Managers
    Finance

    NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products

    Transaction expected to approximately triple NEXGEL's annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing Licensing and acquiring a diversified suite of 6 established regenerative biomaterial products, most with existing insurance reimbursement, along with three new product 510(k) filings planned for 2026, 2027, and 2028 Experienced commercial team is expected to join NEXGEL, significantly expanding the Company's sales reach and operational capabilities LANGHORNE, Pa., March 10, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) pr

    3/10/26 8:45:00 AM ET
    $CELU
    $NXGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments